LLY

1,063.79

-1.23%↓

JNJ

222.81

-0.32%↓

ABBV

215.58

+1.54%↑

UNH

377.18

-0.59%↓

MRK

115.96

+0.86%↑

LLY

1,063.79

-1.23%↓

JNJ

222.81

-0.32%↓

ABBV

215.58

+1.54%↑

UNH

377.18

-0.59%↓

MRK

115.96

+0.86%↑

LLY

1,063.79

-1.23%↓

JNJ

222.81

-0.32%↓

ABBV

215.58

+1.54%↑

UNH

377.18

-0.59%↓

MRK

115.96

+0.86%↑

LLY

1,063.79

-1.23%↓

JNJ

222.81

-0.32%↓

ABBV

215.58

+1.54%↑

UNH

377.18

-0.59%↓

MRK

115.96

+0.86%↑

LLY

1,063.79

-1.23%↓

JNJ

222.81

-0.32%↓

ABBV

215.58

+1.54%↑

UNH

377.18

-0.59%↓

MRK

115.96

+0.86%↑

Kodu・Aktsiate loetelu・Mirati Therapeutics Inc

Mirati Therapeutics Inc

Suletud

SektorTervishoid

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

Max

Soovitused
By TipRanks
Soovitused	Neutraalne
12 kuu keskmine prognoos	-0.05% downside

Uudiste sentiment

By Acuity

100%

316 / 344 Pingereas Healthcare

Mirati Therapeutics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

2. juuni 2026, 20:30 UTC

Tulu

Palo Alto Networks 3Q Revenue Rises as Customers Beef Up Cyber Defenses

2. juuni 2026, 23:58 UTC

Market Talk

Australia's Consumer Sector Expected to Be Stung by Housing Downturn -- Market Talk

2. juuni 2026, 23:46 UTC

Market Talk

Global Equities Roundup: Market Talk

2. juuni 2026, 23:46 UTC

Market Talk

Nikkei May Rise as AI Demand Hopes Continue -- Market Talk

2. juuni 2026, 23:41 UTC

Market Talk

Oil Rises Amid Signs of U.S.-Iran Peace Talks Stalling -- Market Talk

2. juuni 2026, 23:01 UTC

Omandamised, ülevõtmised, äriostud

ACCC Says Owner of Metro Petroleum Brand to Buy the 41 Sites

2. juuni 2026, 23:01 UTC

Omandamised, ülevõtmised, äriostud

ACCC Says Ampol Must Sell 41 Retail Fuel Sites to an Approved Purchaser

2. juuni 2026, 23:00 UTC

Omandamised, ülevõtmised, äriostud

Australia's Competition Regulator Approves Ampol's Purchase of EG Australia With Conditions

2. juuni 2026, 22:57 UTC

Market Talk

Australian Dollar Could Fall Following 1Q GDP Data -- Market Talk

2. juuni 2026, 22:50 UTC

Market Talk

Ulta Beauty Says TikTok Shop Will Provide 'Halo' Effect -- Market Talk

2. juuni 2026, 21:07 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

2. juuni 2026, 21:07 UTC

Market Talk

Tokenized Assets Need Access to Digital-Finance Plumbing -- Market Talk

2. juuni 2026, 21:00 UTC

Tulu

Palo Alto Stock Jumps on Strong Earnings -- Barrons.com

2. juuni 2026, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

2. juuni 2026, 20:46 UTC

Tulu

Palo Alto Stock Jumps on Strong Earnings -- Barrons.com

2. juuni 2026, 20:38 UTC

Tulu

GitLab Stock Rises as the Software Company Raises Guidance on AI Business Momentum -- Barrons.com

2. juuni 2026, 20:21 UTC

Tulu

Palo Alto Stock Jumps on Strong Earnings -- Barrons.com

2. juuni 2026, 20:12 UTC

Tulu

Palo Alto Stock Jumps on Strong Earnings -- Barrons.com

2. juuni 2026, 20:05 UTC

Tulu

Palo Alto Networks 3Q Product Rev $594M

2. juuni 2026, 20:05 UTC

Tulu

Palo Alto Networks Sees FY26 Next-Generation Security ARR $8.9B-$8.95B

2. juuni 2026, 20:05 UTC

Tulu

Palo Alto Networks Raises FY26 View To Adj EPS $3.77-Adj EPS $3.79 >PANW

2. juuni 2026, 20:05 UTC

Tulu

Palo Alto Networks 3Q Subscription and Support Rev $2.41B

2. juuni 2026, 20:05 UTC

Tulu

Palo Alto Networks Sees FY26 Remaining Performance Obligation $20.9B-$21B

2. juuni 2026, 20:05 UTC

Tulu

Palo Alto Networks Sees 4Q Rev $3.345B-$3.355B >PANW

2. juuni 2026, 20:05 UTC

Tulu

Palo Alto Networks Sees 4Q Adj EPS 96c-Adj EPS 98c >PANW

2. juuni 2026, 20:05 UTC

Tulu

Palo Alto Networks on Track to Achieve 40% Adj Free Cash Flow Margin in FY28

2. juuni 2026, 20:05 UTC

Tulu

Palo Alto Networks Raises FY26 View To Rev $11.415B-$11.425B >PANW

2. juuni 2026, 20:05 UTC

Tulu

Palo Alto Networks 3Q Remaining Performance Obligation $18.4B

2. juuni 2026, 20:05 UTC

Tulu

Palo Alto Networks 3Q Adj EPS 85c >PANW

2. juuni 2026, 20:05 UTC

Tulu

Palo Alto Networks 3Q Loss $177M >PANW

Võrdlus sarnastega

Hinnamuutus

Mirati Therapeutics Inc Prognoos

Hinnasiht

By TipRanks

-0.05% langus

12 kuu keskmine prognoos

Keskmine 58.67 USD -0.05%

Kõrge 59 USD

Madal 58 USD

Põhineb 5 Wall Streeti analüütiku instrumendi Mirati Therapeutics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Neutraalne

5 ratings

Osta

Hoia

Müü

Põhineb 5 analüütiku instrumendi Mirati Therapeutics Inc aktsia reitingul - viimase 3 kuu andmed.

Sentiment

By Acuity

316 / 344 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

EBITDA

Ärikasum

Ettevõttest Mirati Therapeutics Inc

Mirati Therapeutics, Inc. is a clinical-stage oncology company. It is focused on developing therapeutics to address the genetic and immunological promoters of cancer. Its clinical programs consist of product candidates, including Adagrasib (MRTX849), MRTX1133, and Sitravatinib. MRTX849 is an oral small-molecule therapy designed to shrink difficult-to-treat cancers harboring the KRAS G12C mutation. MRTX1133 is a small molecule-inhibitor of the KRASG12D mutation, designed to treat patients with unmet need. Sitravatinib is a spectrum-selective receptor tyrosine kinase (RTK) inhibitor that can stimulate the body’s immune response to fight cancer. MRTX849 is in Phase III and Phase I/II clinical trials and MRTX1133 is in preclinical development. Sitravatinib is in a Phase III clinical trial, and Phase I/II clinical trials. It also has additional preclinical discovery programs, which includes first-in-class and best-in-class product candidates designed to address mutations and tumors.